How it works: Bleomycin causes breaks in the DNA strands of cancer cells, stopping their replication and inducing cell death. It is particularly effective against rapidly dividing tumour cells.
Who it’s for:
– Patients diagnosed with Hodgkin’s or non-Hodgkin’s lymphoma
– Those undergoing treatment for testicular cancer (e.g., BEP protocol)
– Individuals with squamous cell carcinoma of the skin, cervix, mouth, or larynx
– Oncological cases requiring fast-acting cytotoxic treatment
– Hodgkin’s and non-Hodgkin’s lymphomas
– Metastatic testicular cancer
– Squamous cell carcinoma of the skin, oral mucosa, cervix, or larynx
– Germ cell tumours
– Used in combination chemotherapy protocols
BLEOCIN is administered intravenously or intramuscularly as part of a chemotherapy protocol. Dosage is individualised based on tumour type, patient body weight, and the specific treatment regimen. Treatment should be supervised by an oncologist in a clinical setting.
Contraindicated in patients with hypersensitivity to bleomycin, severe pulmonary dysfunction, or during pregnancy. Potential side effects include pulmonary fibrosis, skin reactions, fever, fatigue, and bone marrow suppression. Monitoring of lung function and blood counts is essential.
